Sirolimus-eluting and paclitaxel-eluting stents in patients with diabetes: two-year outcomes
This article has no abstract so we have provided the first paragraph of the full text.
Compared with bare-metal stents (BMSs), both sirolimus-eluting stents (SESs) and paclitaxel-eluting stents (PESs) have been shown to reduce the short-term incidence of restenosis and target vessel revascularization in patients with diabetes mellitus. It remains unclear, however, which is the best treatment option with regard to long-term clinical end points such as myocardial infarction and mortality, for which diabetics are at high risk.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
